Page 97

Marzo_2017

367 artículo de revisión 47. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al. Cannabinoids in multiplesclerosis (cams) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-9. 48. Leung L. Cannabis and anditsderivatives: review of medical use. J Am Board Fam Med 2011; 24: 452-62. 49. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in thetreatment of spasticity in patients with multiplesclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004; 10: 417-24. 50. Walker JM, Huang SM. Cannabinoid analgesia. Pharmacol Ther 2002; 95: 127-35. 51. Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, et al. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J Anal Toxicol 2005; 29: 782-9. 52. Vaughan CW, Christie MJ. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Grotenhermen F, Russo E, Editores. New York: The Haworth Integrative Healing Press; 1984. p. 89. 53. Holdcroft A. Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Grotenhermen F, Russo E, Editores. New York: The Haworth Integrative Healing Press; 1984. p. 181. 54. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomised placebo-controlled trial. Lancet 2003; 362: 1517-26. Uso terapéutico de cannabis - M. Avello et al Rev Med Chile 2017; 145: 360-367


Marzo_2017
To see the actual publication please follow the link above